Niraparib: A Poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination

Journal of Medicinal Chemistry

Volumn 58, Issue 8, 2015, Pages 3302-3314

  Jones, Philip ^a,c   Wilcoxen, Keith ^b   Rowley, Michael ^a,d   Toniatti, Carlo ^a,c  

^a Istituto di Ricerche di Biologia Molecolare   (Italy)

^b TESARO Inc   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d MSD Research GmbH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOXORUBICIN; GEMCITABINE; INIPARIB; IRINOTECAN; NIRAPARIB; OLAPARIB; RUCAPARIB; TALAZOPARIB; TEMOZOLOMIDE; VELIPARIB; 2-(4-(PIPERIDIN-3-YL)PHENYL)-2H-INDAZOLE-7-CARBOXAMIDE; BRCA1 PROTEIN; BRCA2 PROTEIN; ENZYME INHIBITOR; INDAZOLE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG SELECTIVITY; ENZYME ACTIVITY; FEMALE; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RAT; SHORT COURSE THERAPY; SINGLE DRUG DOSE; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; VOLUME OF DISTRIBUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; NEOPLASMS;

ANIMALS; BRCA1 PROTEIN; BRCA2 PROTEIN; DRUG DISCOVERY; ENZYME INHIBITORS; HOMOLOGOUS RECOMBINATION; HUMANS; INDAZOLES; MODELS, MOLECULAR; NEOPLASMS; PIPERIDINES; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84928501238     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5018237     Document Type: Article

References (54)

1. Plummer, R. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target Clin. Cancer Res. 2010, 16, 4527-4531
2. Ferraris, D. V. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic J. Med. Chem. 2010, 53, 4561-4584
3. Sandhu, S. K.; Yap, T. A.; de Bono, J. S. The emerging role of poly(ADP-ribose) polymerase inhibitors in cancer treatment Curr. Drug Targets 2011, 12, 2034-2044
4. Basu, B.; Sandhu, S. K.; de Bono, J. S. PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer Drugs 2012, 72, 1579-1590
5. Lee, J. M.; Ledermann, J. A.; Kohn, E. C. PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies Ann. Oncol. 2014, 25, 32-40
6. Hassa, P. O.; Hottiger, M. O. The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases Front. Biosci. 2008, 13, 3046-3082
7. Amé, J.-C.; Spenlehauer, C.; de Murcia, G. The PARP superfamily BioEssays 2004, 26, 882-893
8. Jagtap, P.; Szabó, C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors Nature Rev. Drug Discovery 2005, 4, 421-440
9. Sejas, V.; Chang, P. New PARP targets for cancer therapy Nature Rev. Cancer 2014, 7, 502-509
10. Huber, A.; Bai, P.; de Murcia, J. M.; de Murcia, G. PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development DNA Repair 2004, 3, 1103-1108
11. Durkacz, B. W.; Omidiji, O.; Gray, D. A.; Shall, S. (ADP-ribose)n participates in DNA excision repair Nature 1980, 283, 593-596
12. de Murcia, J. M.; Niedergang, C.; Trucco, C.; Ricoul, M.; Dutrillaux, B.; Mark, M.; Oliver, F. J.; Masson, M.; Dierich, A.; LeMeur, M.; Walztinger, C.; Chambon, P.; de Murcia, G. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 7303-7307
13. Bryant, H. E.; Schultz, N.; Thomas, H. D.; Parker, K. M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N. J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 2005, 434, 913-917
14. Farmer, H.; McCabe, N.; Lord, C. J.; Tutt, A.N. J.; Johnson, D. A.; Richardson, T. B.; Santarosa, M.; Dillon, K. J.; Hickson, I.; Knights, C.; Martin, N. M. B.; Jackson, S. P.; Smith, G. C. M.; Ashworth, A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 2005, 434, 917-921
15. McCabe, N.; Turner, N. C.; Lord, C. J.; Kluzek, K.; Bialkowska, A.; Swift, S.; Giavara, S.; O'Connor, M. J.; Tutt, A. N.; Zdzienicka, M. Z.; Smith, G. C. M.; Ashworth, A. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition Cancer Res. 2006, 66, 8109-8115
16. Nijman, S. M.; Friend, S. H. Cancer. Potential of the synthetic lethality principle Science 2013, 342, 809-811
17. Venkitaraman, A. R. Cancer susceptibility and the functions of BRCA1 and BRCA2 Cell 2002, 108, 171-182
18. Narod, S. A.; Foulkes, W. D. BRCA1 and BRCA2: 1994 and beyond Nature Rev. Cancer 2004, 4, 665-676
19. Menear, K. A.; Adcock, C.; Boulter, R.; Cockcroft, X.-l.; Copsey, L.; Cranston, A.; Dillon, K. J.; Drzewiecki, I.; Garman, S.; Gomez, S.; Javaid, H.; Kerrigan, F.; Knights, C.; Lau, A.; Loh, V. M., Jr.; Matthews, I. T. W.; Moore, S.; O'Connor, M. J.; Smith, G. C. M.; Martin, N. M. B. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2 H -phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1 J. Med. Chem. 2008, 51, 6581-6591
20. Rottenberg, S.; Jaspers, J. E.; Kersbergen, A.; van der Burg, E.; Nygren, A. O. H.; Zander, S. A. L.; Derksen, P. W. B.; de Bruin, M.; Zevenhoven, J.; Lau, A.; Boulter, R.; Cranston, A.; O'Connor, M. J.; Martin, N. M. B.; Borst, P.; Jonkers, J. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 17079-17084
21. De Lorenzo, S. B.; Patel, A. G.; Hurley, R. M.; Kaufmann, S. H. The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells Front. Oncol. 2013, 228, 1-12
22. Murai, J.; Huang, S. Y.; Das, B. B.; Renaud, A.; Zhang, Y.; Doroshow, J. H.; Ji, J.; Takeda, S.; Pommier, Y. Trapping of PARP1 and PARP2 by clinical PARP inhibitors Cancer Res. 2012, 72, 5588-5599
23. Turner, N.; Tutt, A.; Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers Nature Rev. Cancer 2004, 4, 814-819
24. De Summa, S.; Pinto, R.; Sambiasi, D.; Petriella, D.; Paradiso, V.; Paradiso, A.; Tommasi, S. BRCAness: a deeper insight into basal-like breast tumors Ann. Oncol. 2013, 24 (Suppl. 8) viii13-viii21
25. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma Nature 2011, 474, 609-615
26. Banasik, M.; Komura, H.; Shimoyama, M.; Ueda, K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase J. Biol. Chem. 1992, 267, 1569-1575
27. Arundel-Suto, C. M.; Scavone, S. V.; Turner, W. R.; Suto, M. J.; Sebolt-Leopold, J. S. Effects of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on X-ray-induced cellular recovery processes in Chinese hamster V79 cells Radiat. Res. 1991, 126, 367-371
28. Wahlberg, E.; Karlberg, T.; Kouznetsova, E.; Markova, N.; Macchiarulo, A.; Thorsell, A.-G.; Pol, E.; Frostell, Å.; Ekblad, T.; Öncü, D.; Kull, B.; Robertson, G. M.; Pellicciari, R.; Schüler, H.; Weigelt, J. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors Nature Biotechnol. 2012, 30, 283-288
29. Thomas, H. D.; Calabrese, C. R.; Batey, M. A.; Canan, S.; Hostomsky, Z.; Kyle, S.; Maegley, K. A.; Newell, D. R.; Skalitzky, D.; Wang, L.-Z.; Webber, S. E.; Curtin, N. J. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial Mol. Cancer Ther. 2007, 6, 945-956
30. Penning, T. D.; Zhu, G.-D.; Gandhi, V. B.; Gong, J.; Liu, X.; Shi, Y.; Klinghofer, V.; Johnson, E. F.; Donawho, C.; Frost, D. J.; Bontcheva-Diaz, V.; Bouska, J. J.; Osterling, D. J.; Olson, A.; Marsh, K. C.; Luo, Y.; Giranda, V. L. Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1 H -benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer J. Med. Chem. 2009, 52, 514-523
31. Jones, P.; Altamura, S.; Boueres, J.; Ferrigno, F.; Fonsi, M.; Giomini, C.; Lamartina, S.; Monteagudo, E.; Ontoria, J. M.; Orsale, M. V.; Palumbi, M. C.; Pesci, S.; Roscilli, G.; Scarpelli, R.; Schultz-Fademrecht, C.; Toniatti, C.; Rowley, M. Discovery of 2-{4-[(3 S)-piperidin-3-yl]phenyl}-2 H -indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose) polymerase (PARP) inhibitor efficacious in BRCA1 and 2 mutant tumors J. Med. Chem. 2009, 52, 7170-7185
32. DelloRusso, C.; Welcsh, P. L.; Wang, W.; Garcia, R. L.; King, M. C.; Swisher, E. M. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation Mol. Cancer Res. 2007, 5, 35-45
33. Zaremba, T.; Curtin, N. J. PARP inhibitor development for systemic cancer targeting Anticancer Agents Med. Chem. 2007, 7, 515-523
34. Barrows, L. R.; Holden, J. A.; Anderson, M.; D'Arpa, P. The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication Mutat. Res. 1998, 408, 103-110
35. Chaudhuri, A. R.; Hashimoto, Y.; Herrador, R.; Neelsen, K. J.; Fachinetti, D.; Bermejo, R.; Cocito, A.; Costanzo, V.; Lopes, M. Topoisomerase I poisoning results in PARP-mediated replication fork reversal Nature Struct. Mol. Biol. 2012, 19, 417-423
36. Tentori, L.; Graziani, G. Chemopotentiation by PARP inhibitors in cancer therapy Pharmacol. Res. 2005, 52, 25-33
37. Wang, L.; Mason, K. A.; Ang, K. K.; Buchholz, T.; Valdecanas, D.; Mathur, A.; Buser-Doepner, C.; Toniatti, C.; Milas, L. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation Invest. New Drugs 2012, 30, 2113-2120
38. Bridges, K. A.; Toniatti, C.; Buser, C. A.; Liu, H.; Buchholz, T. A.; Meyn, R. E. Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells Oncotarget 2014, 5, 5076-5086
39. Genther Williams, S. M.; Kuznicki, A. M.; Andrade, P.; Dolinski, B. M.; Elbi, C.; O'Hagan, R. C.; Toniatti, C. Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status. Cancer Cell Int. 2015, 15, 14, DOI: 10.1186/s12935-015-0162-8.
40. Papco, G.; Casale, E.; Montagnoli, A.; Cirla, A. PARP inhibitors in cancer therapy: an update Expert Opin. Ther. Pat. 2013, 23, 503-514
41. Shen, Y.; Rehman, F. L.; Feng, Y.; Boshuizen, J.; Bajrami, I.; Elliott, R.; Wang, B.; Lord, C. J.; Post, L. E.; Ashworth, A. BMN673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency Clin. Cancer Res. 2013, 19, 5003-5015
42. Mateo, J.; Ong, M.; Tan, D. S. P.; Gonzalez, M. A.; de Bono, J. S. Appraising iniparib, the PARP inhibitor that never was-what must we learn? Nature Rev. Clin. Oncol. 2013, 10, 688-696
43. O'Shaughnessy, J.; Osborne, C.; Pippen, J. E.; Yoffe, M.; Patt, D.; Rocha, C.; Koo, I. C.; Sherman, B. M.; Bradley, C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer N. Engl. J. Med. 2011, 364, 205-214
44. O'Shaughnessy, J.; Schwartzberg, L. S.; Danso, M. A.; Rugo, H. S.; Miller, K.; Yardley, D. A.; Carlson, R. W.; Finn, R. S.; Charpentier, E.; Freese, M.; Gupta, S.; Blackwood-Chirchir, A.; Winer, E. P. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC) J. Clin. Oncol. 2011, 29 (Suppl) Abstract 1007
45. Patel, A. G.; De Lorenzo, S. B.; Flatten, K. S.; Poirier, G. G.; Kaufmann, S. H. Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro Clin. Cancer Res. 2012, 18, 1655-1662
46. AstraZeneca updates on olaparib and TC-5214 development programmes; AstraZeneca: London, December 20, 2011; http://www.astrazeneca.com/Media/Press-releases/Article/20111220-az-updates-olaparib-TC5214-development (accessed 19 February 2015).
47. Ledermann, J.; Harter, P.; Gourley, C.; Friedlander, M.; Vergote, I.; Rustin, G.; Scott, C. L.; Meier, W.; Shapira-Frommer, R.; Safra, T.; Matei, D.; Fielding, A.; Spencer, S.; Dougherty, B.; Orr, M.; Hodgson, D.; Barrett, J. C.; Matulonis, U. Olaparib maintenance therapy in patients with platinum sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial Lancet Oncol. 2014, 15, 852-861
48. AstraZeneca initiates phase III clinical programme for olaparib, a treatment in development for patients with BRCA mutated ovarian cancer; AstraZeneca: London, September 4, 2013; http://www.astrazeneca.com/Media/Press-releases/Article/astrazeneca-enrollment-patient-phaseIII-olaparib (accessed 19 February 2015).
49. Chung, C. K.; Bulger, P. G.; Kosjek, B.; Belyk, K. M.; Rivera, N.; Scott, M. E.; Humphrey, G.; Limanto, J.; Bachert, D. C.; Emerson, K. M. Process development of C-N cross-coupling and enantioselective biocatalytic reactions for the asymmetric synthesis of niraparib Org. Process Res. Dev. 2014, 18, 215-227
50. Sandhu, S. K.; Schelman, W. R.; Wilding, G.; Moreno, V.; Baird, R. D.; Miranda, S.; Hylands, L.; Riisnaes, R.; Forster, M.; Omlin, A.; Kreischer, N.; Thway, K.; Gevensleben, H.; Sun, L.; Loughney, J.; Chatterjee, M.; Toniatti, C.; Carpenter, C. L.; Iannone, R.; Kaye, S. B.; de Bono, J. S.; Wenham, R. M. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial Lancet Oncol. 2013, 14, 882-892
51. Simon, R.; Freidlin, B.; Rubinstein, L.; Arbuck, S. G.; Collins, J.; Christian, M. C. Accelerated titration designs for phase I clinical trials in oncology J. Natl. Cancer Inst. 1997, 89, 1138-114
52. Curtin, N. J.; Szabó, C. Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond Mol. Aspects Med. 2013, 34, 1217-1256
53. Ledermann, J.; Harter, P.; Gourley, C.; Friedlander, M.; Vergote, I.; Rustin, G.; Scott, C.; Meier, W.; Shapira-Frommer, R.; Safra, T.; Matei, D.; Macpherson, E.; Watkins, C.; Carmichael, J.; Matulonis, U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer N. Eng. J. Med. 2012, 366, 1382-1392
54. Garber, K. PARP inhibitors bounce back Nature Rev. Drug. Discovery 2013, 12, 725-727